 |
Cadence Pharmaceuticals Announces Completion of Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option by Underwriters
Nov 22, 2011
|
11.6 KB |
|
| |
SAN DIEGO, Nov. 22, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced the closing of its previously announced public offering of 21,800,000 shares of its common stock, including 2,800,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters, at a public offering...
|
|
Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Nov 15, 2011
|
11.7 KB |
|
| |
SAN DIEGO, Nov. 15, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that it has priced an underwritten public offering of 19,000,000 shares of its common stock at a price to the public of $3.75 per share. The net proceeds from the sale of the shares, after deducting the underwriting discounts and commissions and e...
|
|
Cadence Pharmaceuticals Announces Proposed Public Offering of Common Stock
Nov 14, 2011
|
11.5 KB |
|
| |
SAN DIEGO, Nov. 14, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced its intention to offer and sell $75 million worth of shares of its common stock in an underwritten public offering. Cadence also expects to grant to the underwriters for the offering a 30-day option to purchase additional shares of common stock to...
|
|
Cadence Pharmaceuticals Reports Third Quarter 2011 Financial Results
Nov 3, 2011
|
23.1 KB |
|
| |
SAN DIEGO, Nov. 3, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and nine months ended September 30, 2011.
For the third quarter...
|
|
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
Nov 2, 2011
|
9.7 KB |
|
| |
SAN DIEGO, Nov. 2, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that the company's President and CEO Ted Schroeder will present the company's corporate overview o...
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results on November 3, 2011
Oct 27, 2011
|
9.9 KB |
|
| |
SAN DIEGO, Oct. 27, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its third quarter ended September 30, 2011 financial results on Thursday, No...
|
|
Cadence Pharmaceuticals to Present at Three Investment Conferences During the Month of September 2011
Aug 31, 2011
|
10.3 KB |
|
| |
SAN DIEGO, Aug. 31, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company will present a corporate overview at the following investment conferen...
|
|
Cadence Pharmaceuticals Reports Second Quarter 2011 Financial Results
Aug 3, 2011
|
23.8 KB |
|
| |
SAN DIEGO, Aug. 3, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and six months ended June 30, 2011.
Cadence commercially launch...
|
|
Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
Aug 2, 2011
|
10.2 KB |
|
| |
SAN DIEGO, Aug. 2, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company will present a corporate overview at the following investment conferences during ...
|
|
Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
Jul 28, 2011
|
13.3 KB |
|
| |
SAN DIEGO, July 28, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) today confirmed that the U.S. Food and Drug Administration (FDA) approved dosing recommendations for OFIRMEV® (acetaminophen) injection remains 4,000 mg per day for adults and adolescents weighing at least 50 kg.
Cadence's announcement follows the issuance...
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2011 Financial Results on August 3, 2011
Jul 27, 2011
|
9.9 KB |
|
| |
SAN DIEGO, July 27, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its second quarter ended June 30, 2011 financial results on Wednesday, Augus...
|
|
Cadence Pharmaceuticals Announces Addition of OFIRMEV® (acetaminophen) Injection to U.S. Military's Joint Deployment Formulary
Jun 7, 2011
|
14.7 KB |
|
| |
SAN DIEGO, June 7, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that OFIRMEV® (acetaminophen) injection has been added to the U.S. Department of Defense's Joint Deployment Formulary (JDF), the core list of pharmaceutical products required for theater-level care of deployed forces. The U.S. Food and Drug Ad...
|
|
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the Jefferies 2011 Global Healthcare Conference on June 9, 2011
Jun 2, 2011
|
9.9 KB |
|
| |
SAN DIEGO, June 2, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that the company's President and CEO Ted Schroeder will present the company's corporate overview o...
|
|
Cadence Pharmaceuticals Reports First Quarter 2011 Financial Results
May 5, 2011
|
23.1 KB |
|
| |
SAN DIEGO, May 5, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the first quarter ended March 31, 2011.
During the first quarter of 2011, ...
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2011 Financial Results on May 5, 2011
Apr 28, 2011
|
9.9 KB |
|
| |
SAN DIEGO, April 28, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today announced that it will release its first quarter ended March 31, 2011 financial results on Thursday, May 5...
|
|
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2011
Apr 26, 2011
|
10.3 KB |
|
| |
SAN DIEGO, April 26, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present a corporate overview at the...
|
|
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Mar 3, 2011
|
21.8 KB |
|
| |
SAN DIEGO, March 3, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the fourth quarter and year ended December 31, 2010.
During the fourth q...
|
|
Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the Cowen and Company 31st Annual Health Care Conference in Boston on March 9, 2011
Mar 2, 2011
|
9.8 KB |
|
| |
SAN DIEGO, March 2, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate...
|
|
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
Feb 25, 2011
|
9.8 KB |
|
| |
SAN DIEGO, Feb. 25, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2010 financial...
|
|
Cadence Pharmaceuticals to Present at Two Investment Conferences in February 2011
Feb 8, 2011
|
10.0 KB |
|
| |
SAN DIEGO, Feb. 8, 2011 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company will present a corporate overview at the following investment conferenc...
|
|
|
